ArticleAlzheimer's research & therapy2020
Combination of plasma amyloid beta
Article in Alzheimer's research & therapy, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 162 papers, 5 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
162 citing papers in PubMed, 5 syntheses or guidelines pooled it, 266 citations in OpenAlex.
- Plasma Biomarkers for Alzheimer's Disease Across the Continuum: A Systematic Review of SIMOA-Based Studies.Cellular and molecular neurobiology · 2026Pooled it
- Utilization of fluid-based biomarkers as endpoints in disease-modifying clinical trials for Alzheimer's disease: a systematic review.Alzheimer's research & therapy · 2024Pooled it
- GFAP as a Potential Biomarker for Alzheimer's Disease: A Systematic Review and Meta-Analysis.Cells · 2023Pooled it
- A population-based meta-analysis of circulating GFAP for cognition and dementia risk.Annals of clinical and translational neurology · 2022Pooled it
- Plasma Aβ as a biomarker for predicting Aβ-PET status in Alzheimer's disease：a systematic review with meta-analysis.Journal of neurology, neurosurgery, and psychiatry · 2022Pooled it
- Multi-night acoustic stimulation is associated with better sleep, amyloid dynamics, and memory in older adults with cognitive impairment.GeroScience · 2024Trial
- Combining plasma phospho-tau and accessible measures to evaluate progression to Alzheimer's dementia in mild cognitive impairment patients.Alzheimer's research & therapy · 2022Trial
- Deep Plasma Proteomics-Based Diagnostic Panel for Early Detection of Amnestic Mild Cognitive Impairment.Journal of proteome research · 2026Article
- Plasma-based neurobiological protein biomarkers as predictors of dementia progression: Insights from longitudinal aging study in India - Diagnostic assessment of dementia.Alzheimer's & dementia : the journal of the Alzheimer's Association · 2026Article
- Article
- Longitudinal Change in Blood-Based Biomarkers and the Association With MRI-Measured Neurodegeneration in Cognitively Unimpaired Individuals.Neurology · 2026Observational
- Hippocampal GFAP in aging: Associations with AD and LATE-NC pathologies and cognitive decline in older adults.Alzheimer's & dementia : the journal of the Alzheimer's Association · 2026Article
- Association of plasma biomarkers with amyloid and tau PET in pre-dementia stages.Alzheimer's & dementia : the journal of the Alzheimer's Association · 2026Article
- Plasma GFAP outperforms CSF GFAP in detecting amyloid pathology and is associated with increased risk of clinical progression in early Alzheimer's disease.The journal of prevention of Alzheimer's disease · 2026Observational
- Visuospatial memory deficit, plasma p-tau217, and Aβ42/Aβ40 ratio enhance sensitivity to identify Aβ PET positivity in individuals with SCD.The journal of prevention of Alzheimer's disease · 2026Article
- Deep sleep slow wave-spindle coupling is selectively linked to plasma amyloid-β levels in older adults in clinical trials.Scientific reports · 2026Article
- Plasma amyloid-β predicts amyloid-β accumulation in PET A- non-demented participants.Journal of Alzheimer's disease : JAD · 2026Article
- Obstructive sleep apnea severity, Alzheimer's disease plasma markers, and CSF brain amyloidosis and tau pathology.Alzheimer's & dementia : the journal of the Alzheimer's Association · 2026Article
- Postmortem Associations Between Alzheimer Disease Pathology and Plasma pTau217, GFAP, and NfL in AD and AD-Related Dementias.Neurology · 2026Article
- Observational
102 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
16 authors at 3 institutions in 4 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundBlood-based biomarkers for Alzheimer's disease (AD) might facilitate identification of participants for clinical trials targeting amyloid beta (Abeta) accumulation, and aid in AD diagnostics. We examined the potential of plasma markers Abeta
methodsWe included individuals with a positive (n = 176: 63 ± 7 years, 87 (49%) females) or negative (n = 76: 61 ± 9 years, 27 (36%) females) amyloid PET status, with syndrome diagnosis subjective cognitive decline (18 PET+, 25 PET-), mild cognitive impairment (26 PET+, 24 PET-), or AD-dementia (132 PET+). Plasma Abeta
resultsAbeta DISCUSSION AND
conclusionsCombination of plasma Abeta
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.